<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335647">
  <stage>Registered</stage>
  <submitdate>22/06/2010</submitdate>
  <approvaldate>23/06/2010</approvaldate>
  <actrnumber>ACTRN12610000520033</actrnumber>
  <trial_identification>
    <studytitle>A randomised placebo controlled crossover trial to evaluate the effects of different doses of taurocholic acid in a suppository on gastrointestinal hormone secretion and appetite in healthy humans.</studytitle>
    <scientifictitle>A randomised placebo controlled crossover trial to evaluate the effects of different doses of taurocholic acid in a suppository on gastrointestinal hormone secretion and appetite in healthy humans.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 diabetes mellitus</healthcondition>
    <healthcondition>Obesity</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Each healthy volunteers will undergo four studies (3 with different doses of taurocholic acid 500mg, 1000mg, and 1500mg and one with control), in double-blind, randomised fashion, separated by 3 - 7 days. On each day the test material will be administered as a suppository.</interventions>
    <comparator>Suppository containing vehicle only containing no additional component</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Plasma concentrations of glucagon-like peptide-1 (GLP-1), Peptide YY (PYY), and oxyntomodulin</outcome>
      <timepoint>T= -5, 10, 30, 60, 90, 120, 180 min, where the suppository is administered at T=0 min</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Appetite scores by visual analogue questionnaire</outcome>
      <timepoint>T= -5, 10, 30, 60, 90, 120, 180 min, where the suppository is administered at T=0 min</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Food intake from an ad libitum buffet meal</outcome>
      <timepoint>Offered over 30 minutes, from 180 - 210 min after the suppository is administered</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Haemoglobin &gt; 135 g/L</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Medications affecting gut function
Alcohol intake &gt;20g daily or cigarette smoking
Significant gastrointestinal disease or surgery
Impaired liver or renal function
Blood donation within 3 months</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>numbered containers</concealment>
    <sequence>computer-generated random number table</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>19/07/2010</anticipatedstartdate>
    <actualstartdate>5/07/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate>8/09/2010</actualenddate>
    <samplesize>12</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Royal Adelaide Hospital</primarysponsorname>
    <primarysponsoraddress>North Terrace
Adelaide
South Australia 5000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council</fundingname>
      <fundingaddress>National Health and Medical Research Council
GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Satiogen Pharmaceuticals Inc.</fundingname>
      <fundingaddress>Satiogen Pharmaceuticals Inc.
350 Tenth Ave, Suite 820 
San Diego, CA 92101</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study aims to establish whether taurocholic acid, administered as a suppository, can stimulate secretion of the gut peptides GLP-1, PYY, and oxyntomodulin, and suppress subsequent appetite and food intake. This information could be useful in designing treatments for type 2 diabetes and obesity.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital Human Research Ethics  Committee</ethicname>
      <ethicaddress>Level 3, 
Hanson Institute 
Royal Adelaide Hospital, 
North Terrace, 
Adelaide SA 5000</ethicaddress>
      <ethicapprovaldate>31/05/2010</ethicapprovaldate>
      <hrec>RAH Protocol No. 100514</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>A/Prof Chris Rayner</name>
      <address>Discipline of Medicine 
Royal Adelaide Hospital 
North Terrace 
Adelaide SA 5000</address>
      <phone>+61 8 82222916</phone>
      <fax>+61 8 82233870</fax>
      <email>chris.rayner@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>A/Prof Chris Rayner</name>
      <address>Discipline of Medicine 
Royal Adelaide Hospital 
North Terrace 
Adelaide SA 5000</address>
      <phone>+61 8 82222916</phone>
      <fax>+61 8 82233870</fax>
      <email>chris.rayner@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>A/Prof Chris Rayner</name>
      <address>Discipline of Medicine 
Royal Adelaide Hospital 
North Terrace 
Adelaide SA 5000</address>
      <phone>+61 8 82222916</phone>
      <fax>+61 8 82233870</fax>
      <email>chris.rayner@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Chris Rayner</name>
      <address>Discipline of Medicine Royal Adelaide Hospital North Terrace Adelaide SA 5000</address>
      <phone>+61 8 82222916</phone>
      <fax />
      <email>chris.rayner@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>